News >

Jagannath Shares Insight on Treatment Strategies in Relapsed/Refractory Myeloma

Ellie Leick
Published: Wednesday, Aug 28, 2019

Sundar Jagannath, MBBS, director of the Multiple Myeloma Program, professor of medicine (hematology and medical oncology), of the Tisch Cancer Institute at Mount Sinai School of Medicine

Sundar Jagannath, MBBS

The relapsed/refractory multiple myeloma space has seen the approvals of several novel agents and combination regimens within the past few years, ultimately leading to an increase in survival for a number of patients, explained Sundar Jagannath, MBBS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x